StockNews.AI
EXAS
StockNews.AI
197 days

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

1. Exact Sciences to release Q4 2024 results on February 19, 2025. 2. Management will discuss financial performance in a live conference call. 3. The company focuses on cancer screening innovations. 4. Exact Sciences has a strong product pipeline with Cologuard and Oncotype tests.

8m saved
Insight
Article

FAQ

Why Bullish?

Anticipation of solid earnings could positively influence EXAS stock. Previous earnings announcements have led to upward price movements.

How important is it?

The scheduled earnings call is likely to affect investor sentiment and stock price.

Why Short Term?

Earnings results are slated for immediate release, impacting stock quickly. Historical trends show short-term reactions to earnings calls.

Related Companies

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

MADISON, Wis.--()--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Fourth quarter 2024 webcast & conference call details

Date:

Wednesday, February 19, 2025

Time:

5 p.m. ET

Webcast:

The live webcast can be accessed at www.exactsciences.com

Telephone:

Domestic callers, dial 888-330-2384

International callers, dial +1 240-789-2701

Access code for both domestic and international callers: 4437608

 A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Erik Holznecht
Exact Sciences Corp.
investorrelations@exactsciences.com
608-800-6605

Related News